钆基纳米颗粒用于头颈癌诊疗一体化特性的评估
研究在头颈CAL33原位瘤雌性NMRI裸鼠模型中评估钆基纳米颗粒AGuIX联合放疗对肿瘤切除后无复发生存的影响。结果显示AGuIX系统给药后被动蓄积于原位瘤,术后AGuIX联合放疗较单纯放疗显著改善无复发生存,中位生存时间196天 vs 75天。
要点
- AGuIX系统给药后被动蓄积于头颈CAL33原位瘤。
- 肿瘤切除后AGuIX联合放疗较单纯放疗显著改善无复发生存。
- AGuIX联合放疗组中位生存时间196天,单纯放疗组75天。
核心结论
- 头颈肿瘤切除后AGuIX注射联合放疗可改善无复发生存。
研究设计与样本
- 在雌性NMRI裸鼠中植入人头颈CAL33原位瘤,于肿瘤植入后19天行肿瘤切除。
- 切除后23天行放疗(10 Gy),于AGuIX静脉注射后1小时进行。
- 通过荧光成像研究AGuIX的生物分布。
主要发现
- AGuIX系统给药后被动蓄积于原位瘤。
- AGuIX联合放疗组中位生存时间196天 vs 单纯放疗组75天,无复发生存显著改善。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aim of the study was to evaluate the benefits of the combination of Gadolinium-based nanoparticles AGuIX and radiotherapy on the recurrence free survival after tumor resection in a head and neck animal orthotopic model. METHODS: Human head and neck CAL33 orthotopic tumors were implanted in female NMRI nude mice. The biodistribution of AGuIX was studied by fluorescence imaging. Tumor resection was performed 19 days after tumor implantation. Radiotherapy was performed 23 days after resection (10 Gy), 1 hour after AGuIX IV injection. RESULTS: After systemic administration, AGuIX passively accumulated in the orthotopic tumors. After tumor surgery, the combination of AGuIX with radiotherapy significantly improved the recurrence free survival and the median survival time (196 days) compared to irradiated only mice (75 days). CONCLUSION: This study demonstrated the improvement of the recurrence free survival following combination of AGuIX injection with radiotherapy after Head and neck tumor resection.
引用
- Quatre R, Jacquet T, Atallah I, et al. Evaluation of the theranostic properties of gadolinium-based nanoparticles for head and neck cancer. Head Neck. 2018. PMID: 30548507. doi:10.1002/hed.25460
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。